Skip to main content
NXTC
NASDAQ Life Sciences

Avere, NextCure's Merger Partner, Unveils Private Placement and Updated Phase 1 Data for Once-Weekly Oral Psoriasis Drug

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$4.721
Mkt Cap
$17.903M
52W Low
$1.55
52W High
$15.74
52W Position info
205% above low
Off High info
70% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

NXTC has more than doubled off its 52-week low of $1.55 on light trading volume (0.2× avg).

Summary

Avere, NextCure's merger partner, disclosed a private placement to fund AVR-001 through Phase 2b readouts and presented updated Phase 1 data showing a 57% PASI 75 response at week 8 for the once-weekly oral psoriasis drug.


Key Events · M&A and Partnerships · NXTC

  • Private Placement to Fund Pipeline

    Avere is conducting a private placement to raise capital, with pre-closing financings expected to fund the combined company through Phase 2b psoriasis and ulcerative colitis readouts and initiation of Phase 3 trials.

  • Updated Phase 1 Data for AVR-001

    The corporate presentation shows AVR-001 achieved a 57% PASI 75 response rate at week 8 in a Phase 1 MAD study, with a safety profile comparable to placebo and no dose-limiting toxicity in chronic toxicology studies.

  • Financing Milestones

    Avere closed on $251 million of convertible notes and completed chronic toxicology studies in non-human primates and rats, supporting advancement into later-stage trials.

  • Anticipated Clinical Milestones

    Phase 2b psoriasis initiation is expected in 2027, with readout in the first half of 2028; Phase 2b ulcerative colitis initiation also in 2027; Phase 3 psoriasis initiation in 2028.


Analysis · NXTC · Life Sciences

Avere Therapeutics, which is merging with NextCure in a deal that leaves legacy NextCure holders with only ~1.89% of the combined company, is now raising capital through a private placement to fund its lead asset AVR-001 through key clinical readouts. The updated corporate presentation shows encouraging Phase 1 data for the once-weekly oral IL-23 receptor antagonist, with PASI 75 response rates of 57% at week 8 and a safety profile supporting advancement. The financing is expected to fund the company through Phase 2b psoriasis and ulcerative colitis readouts and initiation of Phase 3 trials, de-risking the combined entity's pipeline. For NextCure shareholders, the private placement and clinical progress directly impact the value of the post-merger company they will own a tiny fraction of.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NXTC was trading at $4.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.9M. The 52-week trading range was $1.55 to $15.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NXTC - Latest Insights

NXTC
Nov 10, 2026, 4:25 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.78
Real-time Price: $5.60 info
Change: -$0.180 (-3%) info
Market Cap: $27.373M info
NXTC
Nov 10, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.78
Real-time Price: $5.60 info
Change: -$0.180 (-3%) info
Market Cap: $27.373M info
NXTC
Nov 10, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.78
Real-time Price: $5.60 info
Change: -$0.180 (-3%) info
Market Cap: $27.373M info
NXTC
Oct 30, 2026, 8:39 PM EDT
Filing Type: S-4/A
Importance Score:
8
Price at Filing: $6.31
Real-time Price: $5.60 info
Change: -$0.710 (-11%) info
Market Cap: $27.373M info
NXTC
Sep 30, 2026, 7:36 PM EDT
Filing Type: S-4/A
Importance Score:
9
Price at Filing: $5.01
Real-time Price: $5.60 info
Change: +$0.590 (+12%) info
Market Cap: $27.373M info